Ciltacabtagene autoleucel (cilta-cel) was approved for relapsed or refractory MM after four lines of therapy with prior exposure to an IMiD, PI, and anti-CD38 monoclonal antibody, based on the results of the CARTITUDE-1 study (25). The gene discussed is CD38; the disease is Miyoshi myopathy.